Abstract
For management of pain, non-steroidal anti-inflammatory drugs (NSAIDs) play a major role. Use of NSAIDs is associated with toxicity, particularly in the gastrointestinal tract and kidney, whereas the use of COX-2 selective NSAIDs is associated with renal failure. Various approaches such as management of COX-1/COX-2 and 5-LOX/COX-2 inhibitors, use of natural products, formulation, drug modification and synthesis of new chemical entities in search of safer anti-inflammatory drugs reported in literature to overcome serious side effects of NSAIDs is summarized in this review. We have also reported recent findings in the area of synthesis of heterocyclic compounds such as pyrimidine, pyridine, thiazole, triazole, imidazole, oxazole, isooxazole, pyrazole , pyrazolidine, pyrole, acridine derivatives and other related heterocyclic compounds and their role as non-selective, COX-2 selective, LOX selective and COX/LOX dual, inhibitors.
Keywords: Heterocyclic compounds, anti-inflammatory agents, non-steroidal
Current Bioactive Compounds
Title: Heterocyclic Compounds as Anti-Inflammatory Agents
Volume: 3 Issue: 2
Author(s): Sham M. Sondhi, Monica Dinodia, Jaiveer Singh and Reshma Rani
Affiliation:
Keywords: Heterocyclic compounds, anti-inflammatory agents, non-steroidal
Abstract: For management of pain, non-steroidal anti-inflammatory drugs (NSAIDs) play a major role. Use of NSAIDs is associated with toxicity, particularly in the gastrointestinal tract and kidney, whereas the use of COX-2 selective NSAIDs is associated with renal failure. Various approaches such as management of COX-1/COX-2 and 5-LOX/COX-2 inhibitors, use of natural products, formulation, drug modification and synthesis of new chemical entities in search of safer anti-inflammatory drugs reported in literature to overcome serious side effects of NSAIDs is summarized in this review. We have also reported recent findings in the area of synthesis of heterocyclic compounds such as pyrimidine, pyridine, thiazole, triazole, imidazole, oxazole, isooxazole, pyrazole , pyrazolidine, pyrole, acridine derivatives and other related heterocyclic compounds and their role as non-selective, COX-2 selective, LOX selective and COX/LOX dual, inhibitors.
Export Options
About this article
Cite this article as:
Sondhi M. Sham, Dinodia Monica, Singh Jaiveer and Rani Reshma, Heterocyclic Compounds as Anti-Inflammatory Agents, Current Bioactive Compounds 2007; 3 (2) . https://dx.doi.org/10.2174/157340707780809554
DOI https://dx.doi.org/10.2174/157340707780809554 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Review of the Phytochemistry and Biological Activity of Cissus incisa Leaves
Current Topics in Medicinal Chemistry Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology
Current Drug Delivery Activity-Dependent Release of Adenosine: A Critical Re-Evaluation of Mechanism
Current Neuropharmacology Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Meet Our Regional Editor:
Current Drug Discovery Technologies Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Microglia and Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Nutrition and Bone Health: Its Relationship to Osteoporosis
Current Nutrition & Food Science Metabotropic Glutamate Receptors in the Control of Mood Disorders
CNS & Neurological Disorders - Drug Targets A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of <i>Bacopa monnieri</i> against Parkinson's Disease
Current Drug Targets Editorial [Hot topic: An Overview on the Design, Development, Characterization and Applications of Novel Nanomedicines for Brain Targeting (Guest Editor: Eliana B. Souto)]
Current Nanoscience GABAA Receptor Specific Pyrazolopyrimidines as Potential Imaging Agents: In Vivo Characteristics of a New 18F-labelled Indiplon Derivative
Current Radiopharmaceuticals MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued)